Details for New Drug Application (NDA): 217639
✉ Email this page to a colleague
NDA 217639 describes ORSERDU, which is a drug marketed by Stemline Therap and is included in one NDA. It is available from one supplier. There are eight patents protecting this drug. Additional details are available on the ORSERDU profile page.
The generic ingredient in ORSERDU is elacestrant dihydrochloride. One supplier is listed for this compound. Additional details are available on the elacestrant dihydrochloride profile page.
The generic ingredient in ORSERDU is elacestrant dihydrochloride. One supplier is listed for this compound. Additional details are available on the elacestrant dihydrochloride profile page.
Summary for 217639
| Tradename: | ORSERDU |
| Applicant: | Stemline Therap |
| Ingredient: | elacestrant dihydrochloride |
| Patents: | 8 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 217639
Generic Entry Date for 217639*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 217639
Suppliers and Packaging for NDA: 217639
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639 | NDA | Stemline Therapeutics, Inc. | 72187-0101 | 72187-0101-3 | 30 TABLET, FILM COATED in 1 BOTTLE (72187-0101-3) |
| ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639 | NDA | Stemline Therapeutics, Inc. | 72187-0102 | 72187-0102-3 | 30 TABLET, FILM COATED in 1 BOTTLE (72187-0102-3) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 86MG BASE | ||||
| Approval Date: | Jan 27, 2023 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Jan 27, 2028 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Oct 10, 2034 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF AN ER-POSITIVE BREAST CANCER FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY | ||||||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Jan 5, 2038 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Complete Access Available with Subscription
